Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13050
ชื่อเรื่อง: Copper complexes of 8-aminoquinoline and uracils as novel aromatase inhibitors
ผู้แต่ง: Sinthupoom N.
Prachayasittikul V.
Prachayasittikul V.
Pingaew R.
Worachartcheewan A.
Prachayasittikul S.
Ruchirawat S.
วันที่เผยแพร่: 2017
บทคัดย่อ: Currently, aromatase inhibitors (AIs) have been developed for the treatment of breast cancers and other estrogen-related conditions. However, searching for more and new classes of AIs is being investigated. 8-Aminoquinoline (8AQ) is an interesting scaffold to be explored. In particular, 8AQ as its mixed ligands (5-nitrouracil, 5Nu and 5-iodouracil, 5Iu) metal complexes are potential compounds to be studied. Objective: Metal complexes of 8AQ-5Nu/5Iu were investigated for aromatase inhibitory activity and cytotoxicity. Methods: Metal complexes (1-6) and free ligands were evaluated for aromatase inhibitory and cytotoxic activities. Aromatase inhibitory activity of the metal complexes was performed according to a guideline of BD Gentest™ kit using CYP19 enzyme and O-benzyl fluorescein (DBF) as a substrate. Cytotoxic effect of the compounds was tested against normal embryonic lung cell line (MRC) using the MTT assay. Results: Significantly, copper complexes 3 (IC50 = 0.7 μM) and 6 (IC50 = 1.7 μM) were shown to be active aromatase inhibitors with selectivity indices of 24.74 and16.40, respectively. Conclusion: Copper complexes of 8AQ-5Nu (3) and of 8AQ-5Iu (6) were highlighted as novel aromatase inhibitors that could be further developed for therapeutic applications. © 2017 Bentham Science Publishers.
URI: https://ir.swu.ac.th/jspui/handle/123456789/13050
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027875828&doi=10.2174%2f1570180813666161103144822&partnerID=40&md5=95c5ded0a15ab825cf551f944585981c
ISSN: 15701808
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.